Waltham, MA-based Repligen (NASDAQ: RGEN) decided a few years ago that it would be better off abandoning drug development and focusing instead on bioprocessing. Today it’s cut a deal to shed some of its remaining therapeutic baggage. Repligen has licensed its portfolio of experimental, preclinical histone deacetylase inhibitors, or HDACs, to Novato, CA-based rare disease company BioMarin (NASDAQ: BMRN). Repligen is getting just $2 million from BioMarin up front, though it’s eligible to receive another $160 million in various milestone payments if the compounds in the deal make it through clinical testing and are approved by regulators.
Help employers find you! Check out all the jobs and post your resume.
